Summary

This is a Phase 2, randomized, placebo-controlled, multicenter, parallel-group, dose-ranging study in patients with PA to evaluate the efficacy and safety of up to 3 doses of CIN-107 as compared to placebo after 4 weeks of treatment.

Study Name: A Study of CIN-107 in Adults With Primary Aldosteronism (spark-PA)
Status: Recruiting
Conditions: Primary aldosteronism, Hyperaldosteronism
Interventions: Drug: CIN-107 Dose 1, Drug: CIN-107 Dose 2, Drug: CIN-107 Dose 3, Drug: Placebo for CIN-107
Locations: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California; Greenbrae, California; San Francisco, California; Stanford, California; Atlanta, Georgia; Baltimore, Maryland; Ann Arbor, Michigan; Rochester, Minnesota; Houston, Texas; Cincinnati, Ohio; Columbus, Ohio; Chicago, Illinois
Study link: https://clinicaltrials.gov/ct2/show/NCT04605549

To search for other studies by topic, location, or status, go to our Clinical Studies page.

©2021 Primary Aldosteronism Foundation — All Rights Reserved

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.

©2021 Primary Aldosteronism Foundation

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.